Developer docs
API playgroundTry for free, no card

Search company profiles

Vetanic

Full company profile

uuid0034d91

Namestring
Vetanic
Legal namestring
株式会社Vetanic
Websiteurl
vetanic.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Vetanic Inc. is a Japanese biotech venture founded in January 2021, originating from joint research between Keio University and Nihon University, that develops regenerative medicine products for companion animals using proprietary induced pluripotent stem (iPS) cell technology. The company's core technology is a novel non-viral method for establishing clinical-grade animal iPS cells that overcomes pluripotency-induction resistance historically observed in dogs and other companion species, using a unique set of reprogramming factors introduced without viral vectors and an intermediate neural-stem-cell-like stage. Vetanic's flagship product is canine mesenchymal stem cells (ciMSC) differentiated from its proprietary canine iPS cells, targeting systemic inflammatory, autoimmune, and spinal cord injuries in dogs; the platform is also being extended to feline iMSC and equine iPS cells, with a world-first demonstration of canine iPSC-derived peripheral nerve cell differentiation. The company is pursuing Japan's first MAFF-approved veterinary regenerative medicine product under the Pharmaceutical and Medical Device Act, with products intended to be sold as standardized, donor-free (sourced from discarded canine placenta), cryopreserved cell therapy preparations distributed directly to veterinary hospitals upon approval.

Vetanic operates a B2B pharmaceutical distribution model: revenue will come from sale of approved cell therapy products to veterinary hospitals in Japan once MAFF approval is obtained, supplemented by a secondary revenue stream from regenerative medicine research reagents. The company holds an exclusive license to the foundational Japan Patent No. 7591219 (granted November 2024) and the international PCT/JP2020/016924 application, which together protect the core animal iPS cell establishment method. It has raised approximately 657.85 million yen (including capital reserve) through a 150 million yen seed round (July 2021), a 500 million yen Series A (August 2022), additional investment from Yokohama Next, and an April 2026 capital and business alliance with Sysmex Corporation and Kohjin Bio Co., Ltd. The company employs 1–10 staff at its headquarters in Hamamatsucho, Tokyo, and operates an R&D facility, the Shonan Lab, at Shonan Health Innovation Park in Fujisawa, Kanagawa. Co-founders include CEO Akinori Mochizuki (ex-Sosei Group CSO with ~30 years of pharmaceutical industry experience), CSO Prof. Kazuya Edamura (Nihon University), and CTO Prof. Seiji Shiozawa (Kurume University and Keio University).

Short descriptiontext

Vetanic is a Japan-based, university-launched biotech venture developing iPS cell-derived regenerative medicine products — starting with canine mesenchymal stem cells — for sale to veterinary hospitals upon regulatory approval by Japan's Ministry of Agriculture, Forestry and Fisheries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHamamatsucho, Japan
HQ citystring
Hamamatsucho
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary regenerative medicine, animal iPS cells, canine stem cell therapy, cell therapy products, companion animal healthcare
Industry3 codes
PRIMARYHLAMANAD
Cell & Gene Therapy for Veterinary Regeneration
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAMANAA
Stem Cell Therapies (Autologous & Allogeneic)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAMANAH
Neurologic & Spinal Regeneration
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Veterinary Regenerative Medicine
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Veterinary Regenerative Medicine Product Sales
TypeOne Time License
Description

Revenue from the development, manufacturing, and sale of approved animal regenerative medicine products (cell therapy products) derived from iPS cells, including canine MSC products, sold to veterinary hospitals upon regulatory approval from MAFF under the PMD Act.

vetanic.com
2Regenerative Medicine Reagent Research Products
TypeOne Time License
Description

Research, development, manufacture and sale of reagents for regenerative medicine, as listed in the company's registered business description.

vetanic.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Vetanic develops and manufactures regenerative medicine products for animals using proprietary induced pluripotent stem (iPS) cell technology. The company's core offerings include clinical-grade canine iPS cells and canine mesenchymal stem cells (ciMSC) differentiated from those iPS cells, intended for use as licensed veterinary pharmaceutical cell therapy products targeting inflammatory, autoimmune, spinal cord injury and related conditions in companion animals. The company also supplies regenerative medicine research reagents for R&D use.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Nearly 90% of surveyed veterinarians expressed willingness to use an approved MSC preparation (regulatory-approved product)
+3 more records
Product overview1 text field

Vetanic is a university-launched biotech venture specializing in regenerative medicine for animals using iPS cell technology. The company's core offering consists of proprietary clinical-grade canine iPS cells, from which canine mesenchymal stem cells (ciMSC) are differentiated for therapeutic applications. Vetanic operates a dual-product strategy: developing both regenerative medicine products for veterinary use (toward MAFF approval) and regenerative medicine research reagents. The company leverages patented virus-free iPS cell technology established through joint research with Keio University and Nihon University.

Product and service4 records
1Canine iPS Cells
CategoryVeterinary regenerative medicine cell therapy platform
Description

Proprietary clinical-grade canine induced pluripotent stem (iPS) cells developed through virus-free gene introduction with a unique set of reprogramming factors. The cells maintain pluripotency over long periods and are intended as the source material for clinical-grade veterinary regenerative medicine products.

2Canine Mesenchymal Stem Cells (ciMSC)
CategoryVeterinary cell therapy products
Description

Canine mesenchymal stem cells differentiated from Vetanic's proprietary canine iPS cells, developed as a cell therapy product compliant with the Pharmaceuticals and Medical Devices Act. Targeting systemic inflammatory diseases, autoimmune diseases, spinal cord injuries and related conditions in dogs.

3Regenerative Medicine Products for Veterinary Use
CategoryVeterinary pharmaceutical cell therapy products
Description

Animal regenerative medicine products developed using Vetanic's iPS cell technology, targeting approval from Japan's Ministry of Agriculture, Forestry and Fisheries as qualified pharmaceutical products for veterinary use.

4Regenerative Medicine Research Reagents
CategoryResearch reagents and tools
Description

Research reagents for regenerative medicine research, development, manufacturing and sales.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-01
Description

Capital and business alliance with Sysmex Corporation (TSE Prime: 6869, Kobe, Hyogo) to advance veterinary regenerative medicine using iPS cell technology. Sysmex contributes advanced analytical technologies and quality control expertise to support Vetanic's cell therapy product development and manufacturing. A third-party share allotment was executed as the capital foundation of this alliance.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-01
Description

Capital and business alliance with Kohjin Bio Co., Ltd. (TSE Growth: 177A, Sakado, Saitama) combining Vetanic's animal iPS cell technology with Kohjin Bio's custom culture media development capabilities. Prior to this alliance, a basic business partnership agreement was signed in November 2024 for product development and research reagent optimization. Kohjin Bio supports higher quality manufacturing and faster approval acquisition.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-12-05
Description

Joint research agreement with Prof. Shingo Hatotani's research group at Osaka Metropolitan University Graduate School of Veterinary Medicine, Cell Pathology Laboratory. The group has independently established iPS cells from dogs and cats and achieved differentiation into blood lineage cells. This collaboration aims to accelerate social implementation of animal iPS cell technology and provide feedback to Vetanic's product development.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-11-11
Description

Basic agreement signed for development of animal iPS cell-derived regenerative medicine products and animal regenerative medicine research-use products. Kohjin Bio provides expertise in cell culture media development, optimization, and kit development, as well as cell processing contract services, to accelerate Vetanic's R&D pipeline and support MAFF approval.

5Keio University - Prof. Hideyuki Okano
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Technology co-founder and exclusive patent licensor. Prof. Okano's laboratory at Keio University Regenerative Medicine Research Center co-developed the foundational animal iPS cell technology. Vetanic holds exclusive ordinary license to the jointly filed patent (PCT/JP2020/016924).

vetanic.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Technology co-founder and exclusive patent licensor. Prof. Edamura's laboratory at Nihon University Veterinary Surgery developed the canine iPS cell technology in collaboration with Keio University. Vetanic holds exclusive ordinary license to the jointly filed patent. Prof. Edamura serves as external director and CSO of Vetanic.

7Kurume University - Prof. Seiji Shiozawa
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Technology co-founder and exclusive patent licensor. Prof. Shiozawa's laboratory at Kurume University School of Medicine co-developed the animal iPS cell establishment method. Vetanic holds exclusive ordinary license to the jointly filed patent. Prof. Shiozawa serves as external director and CTO of Vetanic.

vetanic.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major global animal health company (incl. former Aratana Therapeutics specialty therapeutics portfolio). Acquired a veterinary cell therapy platform and is a potential partner, acquirer, or competitor given Vetanic's eventual B2B distribution model.

2ReproScience
TypeEmerging player
Description

Stem cell biotechnology company developing veterinary regenerative therapies, notably for spinal cord injury in dogs — the same indication Vetanic targets. Direct comparison in canine neuro-regeneration.

3Cynata Therapeutics
TypeEmerging player
Description

Australia-listed clinical-stage biotech whose Cymerus platform manufactures MSC from induced pluripotent stem cells — the same core technology stack (iPSC → MSC) Vetanic is applying in veterinary medicine. Relevant technology analogue.

TypeDirect peer
Description

Animal health company offering in-clinic regenerative medicine kits (including stem cell therapy) for veterinary use. Now part of Vetoquinol, it competes directly in selling cell-based therapies to veterinary clinics.

5VetStem Biopharma
TypeDirect peer
Description

US-based pioneer in autologous adipose-derived stem cell therapy for dogs, cats, and horses. Closest comparable in delivering regenerative cell therapy products to companion animal hospitals, though it uses autologous rather than iPSC-derived allogeneic cells.

TypeEmerging player
Description

Clinical-stage regenerative medicine company enabling point-of-care autologous adipose-derived stem cell therapy in veterinary and human applications. Comparable in the regenerative medicine-for-animals category.

7Pluristem Therapeutics
TypeEmerging player
Description

Cell therapy company using placenta-derived adherent stromal cells (PLX cells) to produce off-the-shelf regenerative therapies. Comparable in its donor-free, placenta-sourced cell platform concept to Vetanic's placental canine MSC approach.

TypeDirect peer
Description

US-based biotech developing first FDA-approved ready-to-use stem cell therapy for companion animals, raising a large Series B to scale. Direct competitor in the licensed allogeneic veterinary regenerative medicine space.

9Nihon Zenyaku Kogyo (Zenoaq)
TypeBroad incumbent
Description

Leading Japanese veterinary pharmaceutical company marketing a wide portfolio of companion-animal therapeutics. Comparable as a domestic Japanese vet-pharma distribution counterparty and possible commercialization partner for Vetanic's MAFF-approved products.

TypeBroad incumbent
Description

Major Japanese pharmaceutical company with regenerative medicine R&D. Comparable as a Japan-based strategic with the resources to in-license or partner around Vetanic's iPSC platform for cross-species translational development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vetanic

Veterinary Regenerative Medicinevetanic.com

Vetanic is a Japan-based, university-launched biotech venture developing iPS cell-derived regenerative medicine products — starting with canine mesenchymal stem cells — for sale to veterinary hospitals upon regulatory approval by Japan's Ministry of Agriculture, Forestry and Fisheries.

What Vetanic does

Vetanic Inc. is a Japanese biotech venture founded in January 2021, originating from joint research between Keio University and Nihon University, that develops regenerative medicine products for companion animals using proprietary induced pluripotent stem (iPS) cell technology. The company's core technology is a novel non-viral method for establishing clinical-grade animal iPS cells that overcomes pluripotency-induction resistance historically observed in dogs and other companion species, using a unique set of reprogramming factors introduced without viral vectors and an intermediate neural-stem-cell-like stage. Vetanic's flagship product is canine mesenchymal stem cells (ciMSC) differentiated from its proprietary canine iPS cells, targeting systemic inflammatory, autoimmune, and spinal cord injuries in dogs; the platform is also being extended to feline iMSC and equine iPS cells, with a world-first demonstration of canine iPSC-derived peripheral nerve cell differentiation. The company is pursuing Japan's first MAFF-approved veterinary regenerative medicine product under the Pharmaceutical and Medical Device Act, with products intended to be sold as standardized, donor-free (sourced from discarded canine placenta), cryopreserved cell therapy preparations distributed directly to veterinary hospitals upon approval.

Vetanic operates a B2B pharmaceutical distribution model: revenue will come from sale of approved cell therapy products to veterinary hospitals in Japan once MAFF approval is obtained, supplemented by a secondary revenue stream from regenerative medicine research reagents. The company holds an exclusive license to the foundational Japan Patent No. 7591219 (granted November 2024) and the international PCT/JP2020/016924 application, which together protect the core animal iPS cell establishment method. It has raised approximately 657.85 million yen (including capital reserve) through a 150 million yen seed round (July 2021), a 500 million yen Series A (August 2022), additional investment from Yokohama Next, and an April 2026 capital and business alliance with Sysmex Corporation and Kohjin Bio Co., Ltd. The company employs 1–10 staff at its headquarters in Hamamatsucho, Tokyo, and operates an R&D facility, the Shonan Lab, at Shonan Health Innovation Park in Fujisawa, Kanagawa. Co-founders include CEO Akinori Mochizuki (ex-Sosei Group CSO with ~30 years of pharmaceutical industry experience), CSO Prof. Kazuya Edamura (Nihon University), and CTO Prof. Seiji Shiozawa (Kurume University and Keio University).

Vetanic firmographics

Firmographics
Name
Vetanic
Legal name
株式会社Vetanic
Website
https://vetanic.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Vetanic is a Japan-based, university-launched biotech venture developing iPS cell-derived regenerative medicine products — starting with canine mesenchymal stem cells — for sale to veterinary hospitals upon regulatory approval by Japan's Ministry of Agriculture, Forestry and Fisheries.
Ownership category
akta.pro rank

Vetanic industry classification

Industry
Product category
Veterinary Regenerative Medicine
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAMANAD
Cell & Gene Therapy for Veterinary Regeneration
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAMANAA
Stem Cell Therapies (Autologous & Allogeneic)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAMANAH
Neurologic & Spinal Regeneration
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals

Keywords

  • Veterinary regenerative medicine
  • Animal iPS cells
  • Canine stem cell therapy
  • Cell therapy products
  • Companion animal healthcare

Where Vetanic is headquartered

Location

Headquarters

HQ city
Hamamatsucho
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

Vetanic business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Veterinary Regenerative Medicine Product Sales: Revenue from the development, manufacturing, and sale of approved animal regenerative medicine products (cell therapy products) derived from iPS cells, including canine MSC products, sold to veterinary hospitals upon regulatory approval from MAFF under the PMD Act.
  2. Regenerative Medicine Reagent Research Products: Research, development, manufacture and sale of reagents for regenerative medicine, as listed in the company's registered business description.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Vetanic product offering

Product offering

Core offering

Vetanic develops and manufactures regenerative medicine products for animals using proprietary induced pluripotent stem (iPS) cell technology. The company's core offerings include clinical-grade canine iPS cells and canine mesenchymal stem cells (ciMSC) differentiated from those iPS cells, intended for use as licensed veterinary pharmaceutical cell therapy products targeting inflammatory, autoimmune, spinal cord injury and related conditions in companion animals. The company also supplies regenerative medicine research reagents for R&D use.

Product overview

Vetanic is a university-launched biotech venture specializing in regenerative medicine for animals using iPS cell technology. The company's core offering consists of proprietary clinical-grade canine iPS cells, from which canine mesenchymal stem cells (ciMSC) are differentiated for therapeutic applications. Vetanic operates a dual-product strategy: developing both regenerative medicine products for veterinary use (toward MAFF approval) and regenerative medicine research reagents. The company leverages patented virus-free iPS cell technology established through joint research with Keio University and Nihon University.

Differentiator

Problem solved

Functional benefit

Products and services

  • Canine iPS Cells Proprietary clinical-grade canine induced pluripotent stem (iPS) cells developed through virus-free gene introduction with a unique set of reprogramming factors. The cells maintain pluripotency over long periods and are intended as the source material for clinical-grade veterinary regenerative medicine products.
  • Canine Mesenchymal Stem Cells (ciMSC) Canine mesenchymal stem cells differentiated from Vetanic's proprietary canine iPS cells, developed as a cell therapy product compliant with the Pharmaceuticals and Medical Devices Act. Targeting systemic inflammatory diseases, autoimmune diseases, spinal cord injuries and related conditions in dogs.
  • Regenerative Medicine Products for Veterinary Use Animal regenerative medicine products developed using Vetanic's iPS cell technology, targeting approval from Japan's Ministry of Agriculture, Forestry and Fisheries as qualified pharmaceutical products for veterinary use.
  • Regenerative Medicine Research Reagents Research reagents for regenerative medicine research, development, manufacturing and sales.

Quantifiable outcome

  • Nearly 90% of surveyed veterinarians expressed willingness to use an approved MSC preparation (regulatory-approved product)
  • +3 more outcomes

Companies that use Vetanic

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Vetanic technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Vetanic partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and supporting.

  • Sysmex CorporationcoreTechnology or Integration · 1 April 2026Capital and business alliance with Sysmex Corporation (TSE Prime: 6869, Kobe, Hyogo) to advance veterinary regenerative medicine using iPS cell technology. Sysmex contributes advanced analytical technologies and quality control expertise to support Vetanic's cell therapy product development and manufacturing. A third-party share allotment was executed as the capital foundation of this alliance.
  • Kohjin Bio Co., Ltd.coreTechnology or Integration · 1 April 2026Capital and business alliance with Kohjin Bio Co., Ltd. (TSE Growth: 177A, Sakado, Saitama) combining Vetanic's animal iPS cell technology with Kohjin Bio's custom culture media development capabilities. Prior to this alliance, a basic business partnership agreement was signed in November 2024 for product development and research reagent optimization. Kohjin Bio supports higher quality manufacturing and faster approval acquisition.
  • Osaka Metropolitan University - Prof. Shingo Hatotani LaboratorysupportingStrategic or Co-development Partner · 5 December 2024Joint research agreement with Prof. Shingo Hatotani's research group at Osaka Metropolitan University Graduate School of Veterinary Medicine, Cell Pathology Laboratory. The group has independently established iPS cells from dogs and cats and achieved differentiation into blood lineage cells. This collaboration aims to accelerate social implementation of animal iPS cell technology and provide feedback to Vetanic's product development.
  • Kohjin Bio Co., Ltd.coreTechnology or Integration · 11 November 2024Basic agreement signed for development of animal iPS cell-derived regenerative medicine products and animal regenerative medicine research-use products. Kohjin Bio provides expertise in cell culture media development, optimization, and kit development, as well as cell processing contract services, to accelerate Vetanic's R&D pipeline and support MAFF approval.
  • Keio University - Prof. Hideyuki OkanocoreStrategic or Co-development PartnerTechnology co-founder and exclusive patent licensor. Prof. Okano's laboratory at Keio University Regenerative Medicine Research Center co-developed the foundational animal iPS cell technology. Vetanic holds exclusive ordinary license to the jointly filed patent (PCT/JP2020/016924).
  • Nihon University - Prof. Kazuya EdamuracoreStrategic or Co-development PartnerTechnology co-founder and exclusive patent licensor. Prof. Edamura's laboratory at Nihon University Veterinary Surgery developed the canine iPS cell technology in collaboration with Keio University. Vetanic holds exclusive ordinary license to the jointly filed patent. Prof. Edamura serves as external director and CSO of Vetanic.
  • Kurume University - Prof. Seiji ShiozawacoreStrategic or Co-development PartnerTechnology co-founder and exclusive patent licensor. Prof. Shiozawa's laboratory at Kurume University School of Medicine co-developed the animal iPS cell establishment method. Vetanic holds exclusive ordinary license to the jointly filed patent. Prof. Shiozawa serves as external director and CTO of Vetanic.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Vetanic competitors and assessment

Company assessment

Broad incumbents

  • Elanco Animal Health: Major global animal health company (incl. former Aratana Therapeutics specialty therapeutics portfolio). Acquired a veterinary cell therapy platform and is a potential partner, acquirer, or competitor given Vetanic's eventual B2B distribution model.
  • Nihon Zenyaku Kogyo (Zenoaq): Leading Japanese veterinary pharmaceutical company marketing a wide portfolio of companion-animal therapeutics. Comparable as a domestic Japanese vet-pharma distribution counterparty and possible commercialization partner for Vetanic's MAFF-approved products.
  • Astellas Pharma: Major Japanese pharmaceutical company with regenerative medicine R&D. Comparable as a Japan-based strategic with the resources to in-license or partner around Vetanic's iPSC platform for cross-species translational development.

Emerging players

  • ReproScience: Stem cell biotechnology company developing veterinary regenerative therapies, notably for spinal cord injury in dogs — the same indication Vetanic targets. Direct comparison in canine neuro-regeneration.
  • Cynata Therapeutics: Australia-listed clinical-stage biotech whose Cymerus platform manufactures MSC from induced pluripotent stem cells — the same core technology stack (iPSC → MSC) Vetanic is applying in veterinary medicine. Relevant technology analogue.
  • InGeneron: Clinical-stage regenerative medicine company enabling point-of-care autologous adipose-derived stem cell therapy in veterinary and human applications. Comparable in the regenerative medicine-for-animals category.
  • Pluristem Therapeutics: Cell therapy company using placenta-derived adherent stromal cells (PLX cells) to produce off-the-shelf regenerative therapies. Comparable in its donor-free, placenta-sourced cell platform concept to Vetanic's placental canine MSC approach.

Direct peers

  • MediVet (Vetoquinol): Animal health company offering in-clinic regenerative medicine kits (including stem cell therapy) for veterinary use. Now part of Vetoquinol, it competes directly in selling cell-based therapies to veterinary clinics.
  • VetStem Biopharma: US-based pioneer in autologous adipose-derived stem cell therapy for dogs, cats, and horses. Closest comparable in delivering regenerative cell therapy products to companion animal hospitals, though it uses autologous rather than iPSC-derived allogeneic cells.
  • Gallant: US-based biotech developing first FDA-approved ready-to-use stem cell therapy for companion animals, raising a large Series B to scale. Direct competitor in the licensed allogeneic veterinary regenerative medicine space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights8 records

Customer concentration

Vetanic social profiles

Digital presence

Vetanic financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vetanic leadership team

Management profile

Number of profiles

Profiles5 records

Vetanic funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vetanic M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vetanic

What does Vetanic do?

Vetanic develops and manufactures regenerative medicine products for animals using proprietary induced pluripotent stem (iPS) cell technology. The company's core offerings include clinical-grade canine iPS cells and canine mesenchymal stem cells (ciMSC) differentiated from those iPS cells, intended for use as licensed veterinary pharmaceutical cell therapy products targeting inflammatory, autoimmune, spinal cord injury and related conditions in companion animals. The company also supplies regenerative medicine research reagents for R&D use.

Is Vetanic a public or private company?

Vetanic is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vetanic founded?

Vetanic was founded in 2021. It employs 1 to 10 people.

Where is Vetanic based?

Vetanic is headquartered in Hamamatsucho, Japan, in the Asia region.

How does Vetanic make money?

Two revenue lines are on record. Veterinary Regenerative Medicine Product Sales are the primary driver. The others are regenerative Medicine Reagent Research Products.

Who are Vetanic's main competitors?

Broad incumbents on record are Elanco Animal Health, Nihon Zenyaku Kogyo (Zenoaq) and Astellas Pharma. Emerging players are ReproScience, Cynata Therapeutics, InGeneron and Pluristem Therapeutics. Direct peers are MediVet (Vetoquinol), VetStem Biopharma and Gallant.

Does Vetanic have an API?

No public API is recorded for Vetanic.

What industry is Vetanic in?

Vetanic's product category is Veterinary Regenerative Medicine. Its primary akta.pro industry code is HLAMANAD, Cell & Gene Therapy for Veterinary Regeneration, with a secondary code of HLAMANAA, Stem Cell Therapies (Autologous & Allogeneic). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales